|
시장보고서
상품코드
2008050
황반변성증 치료 시장 : 유형별, 병기별, 투여 경로별, 판매 채널별, 지역별Macular Degeneration Treatment Market, By Type, By Stage Of Disease, By Route Of Administration, By Sales Channel, By Geography |
||||||
황반변성증 치료 시장은 2026년에 178억 달러로 추정되고 있으며, 2033년까지 286억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.7%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 178억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 5.70% | 2033년 시장 규모 예측 : | 286억 달러 |
황반변성은 황반(안구 뒤쪽의 빛에 민감한 망막의 중심부)에 영향을 미쳐 중심시력을 상실하게 하는 안질환입니다. 일반적으로 황반 내에 액체나 혈액이 누출되는 비정상적인 혈관에 의해 발생합니다. 황반변성에는 위축형과 삼출형의 두 가지 유형이 있습니다. 근본적인 치료법은 없지만, 노화성 황반변성(AMD) 치료는 질병의 진행을 늦추고 심각한 시력 저하를 예방하는 데 도움이 될 수 있습니다. 다만, 치료법은 병기나 유형에 따라 달라질 수 있습니다. 위축형 AMD는 삼출형보다 진행이 느린 경향이 있지만, 현재로서는 승인된 치료법이나 근본적인 치료법은 없습니다. 위축형이 더 일반적이지만, 보통 천천히(수년간) 진행됩니다. 그러나 치료법은 AMD의 유형에 따라 다릅니다.
시장 역학
망막 질환의 유병률 증가, 고령 인구 증가, 안전하고 효과적인 치료법에 대한 수요 증가, 임상 시험 수 증가는 글로벌 황반변성 치료제 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다. 예를 들어 미국 질병예방통제센터(CDC)에 따르면 노화성 황반변성은 전 세계에서 실명의 주요 원인이며, 65세 이상 미국인의 시력 저하 및 실명의 가장 큰 원인으로 꼽힙니다. 또한 미국의 노인 인구는 2050년까지 4,800만 명에서 8,800만 명으로 거의 두 배로 증가할 것으로 예측되고 있습니다.
2021년 9월 미국 식품의약국(FDA)은 65세 이상 미국인의 시력 저하 및 실명의 주요 원인인 신생혈관성 노화성 황반변성(nAMD)을 포함한 여러 안질환 치료제로 루센티스(라니비주맙 주사제)의 첫 번째 바이오시밀러인 Byooviz( 라니비주맙부누나)를 승인했습니다.
본 조사의 주요 특징.
- 세계의 황반변성 치료제 시장에 대해 조사 분석했으며, 2025년을 기준연도로 하여 예측 기간(2026-2033년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계의 황반변성 치료 시장의 주요 업체를 분석합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 황반변성 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 황반변성증 치료 시장 : 유형별, 2026-2033년
제5장 황반변성증 치료 시장 : 병기별, 2026-2033년
제6장 황반변성증 치료 시장 : 투여 경로별, 2026-2033년
제7장 황반변성증 치료 시장 : 판매 채널별, 2026-2033년
제8장 황반변성증 치료 시장 : 지역별, 2026-2033년
제9장 경쟁 구도
제10장 섹션
KSAMacular Degeneration Treatment Market is estimated to be valued at USD 17.8 Bn in 2026 and is expected to reach USD 28.6 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 17.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.70% | 2033 Value Projection: | USD 28.6 Bn |
Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.
Market Dynamics
Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.
In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.
Key features of the study
- This report provides in-depth analysis of the global macular degeneration treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global macular degeneration treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Bayer AG, REGENXBIO Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Aerie Pharmaceutical Inc., and Bausch Health Companies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global macular degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular degeneration treatment market.
Market Segmentation
- By Type
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- By Stage Of Disease
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
- By Route Of Administration
- Intravenous Route
- Intravitreal Route
- By Sales Channel
- Ambulatory Surgical Centres
- Hospitals
- Other Sales Channels
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Bayer AG
- REGENXBIO Inc.
- Aerie Pharmaceutical Inc.
- Panoptica
- Pfizer Inc.
- Hoffmann-La Roche Ltd.
- Regeneron Pharmaceutical Inc.
- Novartis AG
- Bausch Health Companies Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Stage of Disease
- Market Snapshot, By Route of Administration
- Market Snapshot, By Sales Channel
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing burden of retinal disorders worldwide
- Lack of awareness regarding macular degeneration
- Increasing demand for safe and effective treatment
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Macular Degeneration Treatment Market, By Type, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Dry Age-related Macular Degeneration
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Wet Age-related Macular Degeneration
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
5. Macular Degeneration Treatment Market, By Stage of Disease, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Early-stage AMD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Intermediate AMD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Late-stage AMD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
6. Macular Degeneration Treatment Market, By Route of Administration, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Intravenous Route
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Intravitreal Route
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
7. Macular Degeneration Treatment Market, By Sales Channel, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Ambulatory Surgical Centres
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
- Other Sales Channels
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
8. Macular Degeneration Treatment Market, By Geography, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- REGENXBIO Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aerie Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Panoptica
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
